NAMS Stock Recent News
NAMS LATEST HEADLINES
NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating robust global demand. Lead asset obicetrapib is set to present top-line data in 2H24, with potential approval by 2025-2026. Obicetrapib is a novel oral LDL-c lowering treatment that can be taken with statins and ezetimibe, which we believe to have a peak sales of ~$2bn.
NewAmsterdam Pharma Company N.V. (NAMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
NewAmsterdam is a clinical-stage biopharmaceutical company with a lead therapy candidate that lowers cholesterol levels. The company is examining the therapy to treat high cholesterol levels on patients with cardiovascular disease as well as on Alzheimer's patients.
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET
NewAmsterdam Pharma is a Dutch SMID cap biotech focusing on cardiovascular diseases. NewAmsterdam Pharma has a promising pipeline drug called Obicetrapib that has shown significant potential for LDL-C and apoB lowering.